Tags

Type your tag names separated by a space and hit enter

Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus.
Epilepsia. 1999; 40 Suppl 6:S57-9; discussion S73-4.E

Abstract

Pain is the most disturbing symptom of diabetic neuropathy. Traditionally this type of pain was treated with tricyclic antidepressants which frequently have many side effects. In the study reported here, gabapentin was administered in escalating doses up to 3600 mg per day to eligible patients with moderate to severe diabetic neuropathy pain in a double blind placebo controlled fashion. Gabapentin provided superior and significant pain relief over placebo. In addition, patients taking gabapentin had improvement of sleep scores and a number of items on mood and quality of life questionnaires. Gabapentin was tolerated well with mild and tolerable side effects.

Authors+Show Affiliations

Department of Neurology, University of Wisconsin Medical School, Madison 53792, USA.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10530684

Citation

Backonja, M M.. "Gabapentin Monotherapy for the Symptomatic Treatment of Painful Neuropathy: a Multicenter, Double-blind, Placebo-controlled Trial in Patients With Diabetes Mellitus." Epilepsia, vol. 40 Suppl 6, 1999, pp. S57-9; discussion S73-4.
Backonja MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 1999;40 Suppl 6:S57-9; discussion S73-4.
Backonja, M. M. (1999). Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia, 40 Suppl 6, S57-9; discussion S73-4.
Backonja MM. Gabapentin Monotherapy for the Symptomatic Treatment of Painful Neuropathy: a Multicenter, Double-blind, Placebo-controlled Trial in Patients With Diabetes Mellitus. Epilepsia. 1999;40 Suppl 6:S57-9; discussion S73-4. PubMed PMID: 10530684.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. A1 - Backonja,M M, PY - 1999/10/26/pubmed PY - 1999/10/26/medline PY - 1999/10/26/entrez SP - S57-9; discussion S73-4 JF - Epilepsia JO - Epilepsia VL - 40 Suppl 6 N2 - Pain is the most disturbing symptom of diabetic neuropathy. Traditionally this type of pain was treated with tricyclic antidepressants which frequently have many side effects. In the study reported here, gabapentin was administered in escalating doses up to 3600 mg per day to eligible patients with moderate to severe diabetic neuropathy pain in a double blind placebo controlled fashion. Gabapentin provided superior and significant pain relief over placebo. In addition, patients taking gabapentin had improvement of sleep scores and a number of items on mood and quality of life questionnaires. Gabapentin was tolerated well with mild and tolerable side effects. SN - 0013-9580 UR - https://www.unboundmedicine.com/medline/citation/10530684/Gabapentin_monotherapy_for_the_symptomatic_treatment_of_painful_neuropathy:_a_multicenter_double_blind_placebo_controlled_trial_in_patients_with_diabetes_mellitus_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0013-9580&date=1999&volume=40&issue=&spage=S57 DB - PRIME DP - Unbound Medicine ER -